DEALS: Pfizer buys Exubera from Sanofi-Aventis for $1.3B

January 18, 2006 — 8:01pm ET

DEALS
WHO	WITH	WHAT	SCOOP
Pfizer	Sanofi-Aventis	$1.3B buyout	Pfizer will buy out Sanofi-Aventis' interest in Exubera, an inhaled, dry powder form of human insulin that they were jointly developing.
Perlegen	Genentech	collaboration deal	The companies will study the genetics of cancer and hope to develop new therapies and diagnostic tools for the disease.
KAI Pharmaceuticals	Daiichi Sankyo	$340M licensing deal	The deal is for KAI-9803, a treatment to reduce the damage caused by reperfusion during angioplasty.
Avigen	Sanochemia Pharmazeutika	$100M licensing deal	The deal is for a brain spasm drug.
Forest	Mylan	$75M licensing deal	Forest will pay Mylan for the development rights to the hypertension drug nebivolol in the U.S. and Canada.
CancerVax	Micromet	$126. 7M merger	CancerVax has agreed to team up with Germany's Micromet in a buyout.
Connetics	PediaMed Pharmaceuticals	$12.5M acquisition	Connetics will acquire the sales organization of PediaMed.
Becton, Dickinson	GeneOhm Sciences	buyout	Becton, Dickinson is buying GeneOhm Sciences for $230M and $25M in incentive payments; GeneOhm makes infection tests.
Affymetrix	Duke University	collaboration deal	Duke researchers will use Affymetrix's GeneChip microarray technology to look for RNA and DNA patterns that can be used to classify and treat cardiovascular and cancer disease.

Most Popular Stories